Korean J Helicobacter Up Gastrointest Res.  2018 Jun;18(2):120-126. 10.7704/kjhugr.2018.18.2.120.

First-line Helicobacter pylori Eradication with Standard Triple Therapy and Concomitant Therapy: A Retrospective Study

• Lee MW
• Kim GH
• Han SY
• Park YJ
• Jeon HK
• Lee BE
• Song GA

• KMID: 2439804
• DOI: http://doi.org/10.7704/kjhugr.2018.18.2.120

Abstract

BACKGROUND/AIMS
The eradication rate of Helicobacter pylori with standard triple therapy as a first-line treatment has decreased to 70~85%. Recently, concomitant therapy has been reported to overcome this decrease in eradication rate to some degree. The aim of this retrospective study was to compare the efficacy of 7-day concomitant therapy with that of 7-day standard triple therapy as a first-line treatment.
MATERIALS AND METHODS
Between March 2013 and February 2017, the medical records of 261 patients who received 7-day standard triple therapy or 7-day concomitant therapy as a first-line H. pylori eradication therapy were retrospectively evaluated. Successful eradication was confirmed using the 13C-urea breath test 6 to 8 weeks after the end of the eradication therapy.
RESULTS
This study included 261 patients, 140 patients in the standard triple therapy group and 121 in the concomitant therapy group. The H. pylori eradication rate by intention-to-treat analysis was 60.0% in the standard triple therapy group and 81.0% in the concomitant therapy group (P<0.001). In the per-protocol analysis, the H. pylori eradication rates in the standard triple therapy and concomitant therapy groups were 69.4% and 88.3%, respectively (P<0.001).
CONCLUSIONS
Concomitant therapy was more effective as a first-line H. pylori eradication therapy than the standard triple therapy.

Keyword

Concomitant therapy; Disease eradication; Helicobacter pylori; Standard therapy

MeSH Terms

Breath Tests
Disease Eradication
Helicobacter pylori*
Helicobacter*
Humans
Medical Records
Retrospective Studies*